

- *Advanced clinical stage*
- *Dual use drug:  
warfighters & civilians*
- *Near-term revenue*

**KEY FACTS**

- \$155M Capitalization
  - \$100M Non-dilutive
  - \$ 55M Equity
- Fully funded to Emergency Use Authorization
- Commercial revenue within 24 months
- 19 issued / 8 pending patents
- Orphan Drug; FDA Fast Track
- NDAA FY26 Congressional Testimony

**MANAGEMENT TEAM**




**Ronald Zenk, CEO**  
Founder; DoD Licensing Liaison; \$45M Appropriations



**Adm Colin Chinn, MD, CMO** 38 Years Navy fmr Jt Staff Surgeon, Pentagon 2017–2019



**Michael Kaytor, PhD, CSO** Biochemistry and Biophysics; \$45M NIH Funding Lead



**Timothy Morris, COO** Served as CFO, COO for multiple public pharma companies

**BOARD OF DIRECTORS**

- Adm. Matt Nathan, MD, Chairman 37th Surgeon General US Navy
- Gen. Barbara Holcomb, fmr Commander, U.S. Army Medical Research and Materiel Command
- Jake Nunn, MBA, Cap'l Mkts Partner, SR One; fmr Partner, NEA
- Thomas Jasper, CPA, COO Choice Bank
- John Dykstra, fmr COO Humanetics

**COMPANY OVERVIEW**

Humanetics is a clinical-stage specialty pharma company developing **BIO 300 (aka BYOGRAYZ™)**, the most advanced drug in the industry to prevent radiation damage, also referred to as a RadioProtectant.

**PROBLEM: TOXIC RADIATION**



Warfighters



Nuclear Power Facilities




Cancer Radiation Therapy

Global threats of toxic radiation are rising; there is no available agent to protect military and civilian populations from harm. Likewise, there is no approved drug to protect healthy tissue from the harmful effects of cancer radiation therapy.

**BYOGRAYZ: A POWERFUL NEW RADIOPROTECTANT**

- Developed by U.S. Military; licensed to Humanetics
- Whole body protection
- Self-administered daily oral dosing (< one tablespoon)
- No needles, syringes, or refrigeration

**DUAL USE MARKET OPPORTUNITIES**



**Medical Countermeasure**

U.S. Military: \$126M  
U.S. HHS (Civilians): \$590M  
EU; Middle East; Asia: \$290M

**Cancer Radiation Therapy (Cases; US)**

1. Lung: 100,000/yr; \$1.6B
2. Head & Neck: 50,000/yr; \$725M
3. Prostate: 150,000/yr; \$4.0B

**CLINICAL DATA IN FOUR TRIALS; ROBUST SAFETY PROFILE**

- Phase 1b/2a in NSCLC: lower adverse event rates; improved tumor response; no dose limiting toxicities reported
- Phase 2 in Long COVID: improved pulmonary function and QoL; well-tolerated

**SERIES B PREFERRED (UP TO \$10M)**

- Supports Phase 2 clinical development in cancer and pulmonary indications